Literature DB >> 14681888

Diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita.

Peter B Kang1, Hart G W Lidov, William S David, Alcy Torres, Douglas C Anthony, H Royden Jones, Basil T Darras.   

Abstract

Arthrogryposis multiplex congenita (AMC), a clinical syndrome characterized by multiple congenital joint contractures, frequently is caused by lesions in the peripheral nervous system. Two standard tests for the evaluation of the motor unit are nerve conduction studies/electromyography (NCS/EMG) and muscle biopsy. We reviewed the diagnostic value of these two studies in the evaluation of AMC over a 23-year period, analyzing 38 patients with AMC who had NCS/EMG, muscle biopsy, or both. Final diagnoses were classified as neurogenic (8 patients), myopathic (10 patients), "other" (12 patients), or unknown (8 patients). Neither test alone had consistently high sensitivities, positive predictive values, or specificities. However, when NCS/EMG and muscle biopsy were concordant for neurogenic or myopathic findings, they were more accurate than either test alone, especially for neurogenic diseases. Test results were most commonly discordant in patients with "other" or unknown diagnoses. These findings suggest that when the clinical evaluation indicates a specific syndromic, developmental, or exogenous cause, NCS/EMG and muscle biopsy are not helpful and may not need to be performed. When the history, examination, and genetic evaluation are unrevealing, NCS/EMG and muscle biopsy together provide valuable diagnostic information.

Entities:  

Mesh:

Year:  2003        PMID: 14681888     DOI: 10.1002/ana.10769

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  1 in total

1.  Diagnostic approach to neonatal hypotonia: retrospective study on 144 neonates.

Authors:  Vincent Laugel; Mireille Cossée; Jacqueline Matis; Anne de Saint-Martin; Andoni Echaniz-Laguna; Jean-Louis Mandel; Dominique Astruc; Michel Fischbach; Jean Messer
Journal:  Eur J Pediatr       Date:  2007-07-20       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.